Printer Friendly

TOCOR II, INC. AND CENTOCOR, INC. INCREASE SIZE OF UNIT OFFERING

 TOCOR II, INC. AND CENTOCOR, INC. INCREASE SIZE OF UNIT OFFERING
 MALVERN, Pa., Jan. 15 /PRNewswire/ -- Centocor, Inc. (NASDAQ: CNTO) today announced that Centocor and Tocor II, Inc., a newly formed International Business Company incorporated under the laws of the British Virgin Islands, have filed an amended Registration Statement with the Securities and Exchange Commission to increase their proposed public offering from 1,500,000 units to 2,000,000 units, each unit consisting of one callable common share of Tocor II, one Series T warrant to purchase one common share of Centocor and one callable warrant to purchase one common share of Centocor. Of the 2,000,000 units to be offered, 1,600,000 units will be offered in the United States and Canada and 400,000 units will be offered in a concurrent international offering outside the United States and Canada.
 The offering in the United States and Canada will be managed by PaineWebber Incorporated, The First Boston Corporation, Hambrecht & Quist Incorporated and J.P. Morgan Securities Inc. The international offering will be managed by PaineWebber International, Credit Suisse First Boston Limited, Hambrecht & Quist Incorporated and J.P. Morgan Securities Ltd.
 Tocor II will receive all of the net proceeds from the offering. These funds will be used by Tocor II to engage Centocor to conduct research and development relating to small peptide molecule products for the treatment of human disease. Centocor will have an option, through Dec. 31, 1995, to acquire all of the callable common stock of Tocor II at specified prices. If the purchase option is exercised, the callable warrants will terminate and will not become exercisable.
 Centocor, a human health care company founded in 1979, develops, manufactures and markets innovative products for human health care utilizing monoclonal antibody technology.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The offering will be made only by means of a prospectus. This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of those securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 /delval/
 -0- 1/15/92
 /CONTACT: Richard Koenig of Centocor, 215-651-6122/
 (CNTO) CO: Centocor, Inc.; Tocor II, Inc. ST: Pennsylvania IN: MTC SU: OFR


CC -- PH021 -- 0159 01/15/92 16:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1992
Words:414
Previous Article:GEM INTERNATIONAL NETWORK TO INTRODUCE GLOBAL GEM MARKET SYSTEM
Next Article:AMERICAN HOME PRODUCTS REPORTS RECORD SALES AND EARNINGS FOR 1991
Topics:


Related Articles
CENTOCOR REPORTS RESULTS OF OPERATIONS FOR THE QUARTER ENDED SEPT. 30, 1991
CENTOCOR AND CORVAS SIGN ANTIBODY AGREEMENT
TOCOR II AND CENTOCOR FILE UNIT OFFERING
SWORD financing of innovation in the biotechnology industry.
SUIT FILED SEEKING TO BLOCK EXCHANGE OFFER FOR TOCOR II UNITS
U.S. GOVERNMENT BEGINS STUDY OF CENTOCOR'S CenTNF (TM) (cA2) IN COMBINATION WITH IL-2 TO TREAT HIV-1 INFECTION
CENTOCOR REPORTS FOURTH QUARTER AND FULL-YEAR 1995 FINANCIAL RESULTS
CENTOCOR REPORTS FIRST QUARTER 1996 FINANCIAL RESULTS
Centocor to Settle Litigation
Centocor Completes Registration Statement for Convertible Subordinated Debentures

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters